A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.

导出 LinkOut

翻译打印收藏纠错

第一作者： Naoshi,Odagiri

第一单位： Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, 545-8585, Japan.

作者： Naoshi,Odagiri ^[1] ; Akihiro,Tamori ^[2] ; Kohei,Kotani ^[1] ; Hiroyuki,Motoyama ^[1] ; Etsushi,Kawamura ^[1] ; Atsushi,Hagihara ^[1] ; Hideki,Fujii ^[1] ; Sawako,Uchida-Kobayashi ^[3] ; Masaru,Enomoto ^[1] ; Norifumi,Kawada ^[1]

作者单位： Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, 545-8585, Japan. ^[1] Department of Internal Medicine, Kashiwara Municipal Hospital, 1-7-9 Hozenji, Kashiwara City, Osaka, 582-0005, Japan. tamori-a@omu.ac.jp. ^[2] Department of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, 545-8585, Japan. ^[3]

关键词 Atezolizumab Bevacizumab Hepatocellular carcinoma Immune checkpoint inhibitor Pseudoprogression

主题词男(雄)性(Male);人类(Humans);中年人(Middle Aged);癌, 肝细胞(Carcinoma, Hepatocellular);肝肿瘤(Liver Neoplasms);治疗结果(Treatment Outcome);化学栓塞, 治疗性(Chemoembolization, Therapeutic)

DOI 10.1007/s12328-023-01761-6

PMID 36739366

发布时间 2023-05-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交